A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

NCT01879332 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy

Interventions

DRUG: Placebo
DRUG: BIA 2-093 3000 mg once daily
DRUG: BIA 2-093 3600 mg once daily

Sponsor

Bial - Portela C S.A.